Boston Scientific has obtained an approval in Europe for the latest addition to its pulsed field ablation portfolio, with the ...

The FDA encourages sponsors to discuss plans to use animal testing alternatives, called new approach methodologies or NAMs, ...

Designed for use in doctor’s offices, clinics and emergency rooms, the PCR diagnostic aims to deliver results in fewer than ...

Novocure, the Swiss maker of a wearable electric field therapy to treat certain cancers, has named veteran insider Frank ...

Imvax has shrugged off the failure of its phase 2b brain cancer trial to hit its primary endpoint, reporting evidence of ...

Mere weeks after being named the nation’s top drug regulator, Richard Pazdur, M.D., is taking steps to retire as head of the FDA’s Center for Drug Evaluation and Research at the end of this month, | ...

Makary announced in May that he intended for the FDA to fully integrate generative AI into its work by the end of June; that ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement | Akebia Therapeutics has struck a deal for Q32 ...

But the biotech’s newest update has failed to garner the same investor enthusiasm, with the company’s stock nearly halved following the data drop.

Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its ...

Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.

Angelini’s investments will be made through its Angelini Ventures arm. EIB and Angelini plan to support between seven and 10 ...